140 related articles for article (PubMed ID: 37093266)
1. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Patel A; Bhatt N; Prakash SS; Biswas G; Nagarkar R; Roy B; Samal P; Agrawal N; Meshram S; Kaushal A; Satheesh CT; Wategaonkar R; Thiagarajan KV; Jain K; Vijayaveeran P; Mukherjee K; Singh K; Patil T; Jain A; Dolai TK; Jain M; Hingmire S; Gupta TC; Lakshmaiah KC; Rajamanickam D; Nemade B; Goyal V; Mahato P; Mendiratta SK; Doshi M
Cancer Chemother Pharmacol; 2023 Jun; 91(6):457-468. PubMed ID: 37093266
[TBL] [Abstract][Full Text] [Related]
2. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
Shi Y; Song Y; Qin Y; Zhang Q; Han X; Hong X; Wang D; Li W; Zhang Y; Feng J; Yang J; Zhang H; Jin C; Yang Y; Hu J; Wang Z; Jin Z; Su H; Wang H; Yang H; Fu W; Zhang M; Zhang X; Chen Y; Ke X; Liu L; Yu D; Chen G; Wang X; Jin J; Sun T; Du X; Cheng Y; Yi P; Zhao X; Ma C; Cheng J; Chai K; Luk A; Liu E; Zhang X
J Hematol Oncol; 2020 Apr; 13(1):38. PubMed ID: 32299513
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.
Song Y; Zhou H; Zhang H; Liu W; Shuang Y; Zhou K; Lv F; Xu H; Zhou J; Li W; Wang H; Zhang H; Huang H; Zhang Q; Xu W; Ge Z; Xiang Y; Wang S; Gao D; Yang S; Lin J; Wang L; Zou L; Zheng M; Liu J; Shao Z; Pang Y; Xia R; Chen Z; Hou M; Yao H; Feng R; Cai Z; Zhang M; Ran W; Liu L; Zeng S; Yang W; Liu P; Liang A; Zuo X; Zou Q; Ma J; Sang W; Guo Y; Zhang W; Cao Y; Li Y; Feng J; Du X; Zhang X; Zhao H; Zhou H; Yu J; Sun X; Zhu J; Qiu L
Adv Ther; 2021 Apr; 38(4):1889-1903. PubMed ID: 33751401
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.
Viswabandya A; Shah S; Mukhopadhyay A; Nagarkar RV; Batra SS; Lopez-Lazaro L; Kankanwadi S; Srivastava A
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31809224
[TBL] [Abstract][Full Text] [Related]
5. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Candelaria M; González DE; Delamain MT; Bär DO; Beniwal SK; Dasappa L; Flores DH; Querol J; Guan TS; Lipatov ON; Volodicheva EM; Patel M; Safaee Nodehi SR; Fogliatto L; Paravisini A; Perez Diaz L;
Leuk Lymphoma; 2019 Dec; 60(14):3375-3385. PubMed ID: 31272251
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.
Gota V; Karanam A; Rath S; Yadav A; Tembhare P; Subramanian P; Sengar M; Nair R; Menon H
Cancer Chemother Pharmacol; 2016 Aug; 78(2):353-9. PubMed ID: 27329361
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
Kim WS; Buske C; Ogura M; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Osmanov D; Kwak LW; Lee SJ; Lee SY; Bae YJ; Coiffier B
Lancet Haematol; 2017 Aug; 4(8):e362-e373. PubMed ID: 28712940
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation.
Ganesan P; Sagar TG; Kannan K; Radhakrishnan V; Rajaraman S; John A; Sundersingh S; Mahajan V; Ganesan TS
Indian J Cancer; 2017; 54(2):430-435. PubMed ID: 29469072
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera
Shi Y; Zhang Q; Hong X; Wang Z; Gao Y; Zou L; Cen H; Gui L; Li Y; Feng J; Wang Z; Zhang M; Jin C; Zhang W; Hu J; Zheng C; Zheng Z; Zhang L; Chen S; Huang Y; Tang Y; Gao Y; Hao M; Li X; Chang C; Yang H; Wu H; Shen L; Ke X; Zhang L; Xi Y; Yang L; Xie L; Gai W; Ji Y
Hematol Oncol; 2022 Dec; 40(5):930-940. PubMed ID: 35858181
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
13. Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Poddubnaya IV; Alekseev SM; Kaplanov KD; Lukavetskyy LM; Rekhtman GB; Dolai TK; Attili VSS; Bermúdez CD; Isaev AA; Chernyaeva EV; Ivanov RA
Hematol Oncol; 2020 Feb; 38(1):67-73. PubMed ID: 31724191
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Ogura M; Sancho JM; Cho SG; Nakazawa H; Suzumiya J; Tumyan G; Kim JS; Lennard A; Mariz J; Ilyin N; Jurczak W; Lopez Martinez A; Samoilova O; Zhavrid E; Yañez Ruiz E; Trneny M; Popplewell L; Coiffier B; Buske C; Kim WS; Lee SJ; Lee SY; Bae YJ; Kwak LW
Lancet Haematol; 2018 Nov; 5(11):e543-e553. PubMed ID: 30389036
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience.
Özbalak M; Güzel Mastanzade M; Özlük Ö; Tiryaki TO; Erdem S; Özbalak EP; Elverdi T; Yönal Hindilerden İ; Altay AY; Yeğen G; Eşkazan AE; Ar MC; Yenerel MN; Soysal T; Nalçacı M; Ferhanoğlu B; Kalayoğlu Beşışık S
Turk J Haematol; 2022 Dec; 39(4):254-261. PubMed ID: 35657203
[TBL] [Abstract][Full Text] [Related]
17. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
18. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
19. Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
Svensson RJ; Ooi QX; Friberg LE; Maharaj N; Reddy PK; López-Lázaro L; Hansson E
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):154-167. PubMed ID: 36330695
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
